Glioma, a type of tumor that affects the glial cells in the brain, is the most common form of central nervous system tumor. Astrocytic tumors are the most common histological subtype of glioma, and glioblastoma accounts for most astrocytic tumors. Glioblastoma is the most aggressive glioma subtype and has the poorest prognosis. R&D activity focuses on glioblastoma. Surgical resection, radiotherapy, and chemotherapy constitute the mainstay of glioma management. Drug treatment options are limited, and the therapeutic arsenal is widely regarded as suboptimal. Temozolomide (generics) is the standard of care for newly diagnosed glioblastoma, and Avastin (Roche/Genentech’s bevacizumab) is commonly prescribed for recurrent glioblastoma. Therapeutic vaccines and an immune checkpoint inhibitor are in Phase III clinical development for glioblastoma; these novel therapies hold promise of fulfilling unmet need for more effective therapies in this difficult-to-treat indication.

Questions Answered in This Report:

  • Glioma is a histologically diverse disease, and patients can be diagnosed with grade I-IV disease. How does treatment differ depending on disease histology and tumor grade?

  • Bevacizumab is not approved for the treatment of glioblastoma in Europe, and it has accelerated approval only for the treatment of recurrent glioblastoma in the United States. What are thought leaders’ opinions on bevacizumab in glioblastoma? How is bevacizumab currently used for the treatment of glioblastoma in the markets under study? How is development of bevacizumab for glioblastoma being pursued? What is Decision Resources Group’s stance on new clinical data influencing bevacizumab’s regulatory status in the markets under study?

  • Immune checkpoint inhibitors have generated excitement in the oncology community and gained regulatory approval in melanoma and lung cancer. Do interviewed physicians think this drug class may play a role in the treatment of glioblastoma?

  • Several therapeutic vaccines are in late-phase development for glioblastoma. What are experts’ opinion of these agents? What percentage of patients will likely benefit from treatment with these agents? How will management of newly diagnosed and recurrent glioblastoma change over our forecast period?


Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.

Primary research: 8 country-specific interviews with thought leaders.

Epidemiology: Diagnosed incident cases of low-grade glioma (WHO grade I-II), high-grade glioma (anaplastic glioma; WHO grade III), glioblastoma (WHO grade IV; primary cases ), and transformed cases of non-glioblastoma astrocytic glioma (WHO grade I-III; secondary cases).

Population segments in market forecast: First-line glioblastoma (newly diagnosed and transformed non-glioblastoma astrocytic glioma cases), second-line glioblastoma (first recurrence), third-line glioblastoma (second recurrence).

Phase III: 7 drugs; Phase II: 15 drugs; Phase I: 3 drugs.

Author(s): Karen Pomeranz, M.Sc., Ph.D.
Nishant Kumar, B.Sc., M.P.H.

Related Reports

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details